Should I buy or sell Senti Biosciences stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Senti Biosciences in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SNTI shares. View SNTI analyst ratings or view top-rated stocks .

What is Senti Biosciences' stock price target for 2024?

1 equities research analysts have issued twelve-month target prices for Senti Biosciences' shares. Their SNTI share price targets range from $6.00 to $6.00. On average, they expect the company's stock price to reach $6.00 in the next twelve months. This suggests a possible upside of 1,835.5% from the stock's current price. View analysts price targets for SNTI or view top-rated stocks among Wall Street analysts .

How have SNTI shares performed in 2024?

Senti Biosciences' stock was trading at $0.66 on January 1st, 2024. Since then, SNTI shares have decreased by 53.0% and is now trading at $0.31. View the best growth stocks for 2024 here .

When is Senti Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our SNTI earnings forecast .

How were Senti Biosciences' earnings last quarter?

Senti Biosciences, Inc. (NASDAQ:SNTI) issued its earnings results on Thursday, March, 21st. The company reported ($0.42) earnings per share (EPS) for the quarter. Senti Biosciences had a negative trailing twelve-month return on equity of 74.59% and a negative net margin of 2,692.82%.

What ETF holds Senti Biosciences' stock?

ARK Genomic Revolution ETF holds 1,560,153 shares of SNTI stock, representing 0.04% of its portfolio.

How do I buy shares of Senti Biosciences?

Shares of SNTI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:SNTI

Senti Biosciences (SNTI) Stock Price, News & Analysis

→ Top 5 Tech Stocks to Buy for 2024 (From Daily Market Alerts) (Ad)

Free SNTI Stock Alerts

$0.31

+0.01 (+3.33%)

(As of 04/17/2024 ET)

Compare

Today's Range: $0.29
▼
$0.33
50-Day Range: $0.30
▼
$0.47
52-Week Range: $0.27
▼
$1.22

Volume: 31,513 shs
Average Volume: 110,764 shs
Market Capitalization: $14.18 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $6.00

Get Senti Biosciences alerts:

Senti Biosciences MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 1,835.5% Upside
$6.00 Price Target
Short Interest: Healthy
0.80% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.09 out of 5 stars

Medical Sector

483rd out of 913 stocks

Biological Products, Except Diagnostic Industry

71st out of 134 stocks

3.5

Analyst's Opinion

Consensus Rating
Senti Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Senti Biosciences has received no research coverage in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
0.80% of the float of Senti Biosciences has been sold short.
Short Interest Ratio / Days to Cover
Senti Biosciences has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Senti Biosciences has recently decreased by 4.21%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Senti Biosciences does not currently pay a dividend.
Dividend Growth
Senti Biosciences does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for SNTI.

N/A

News and Social Media Coverage

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Senti Biosciences insiders have not sold or bought any company stock.
Percentage Held by Insiders
12.50% of the stock of Senti Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 25.73% of the stock of Senti Biosciences is held by institutions.

0.6

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Senti Biosciences is -0.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Senti Biosciences is -0.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Senti Biosciences has a P/B Ratio of 0.21. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Market Moving Trends

Top 5 AI Stocks to Buy for 2024

5 Best AI Stocks to Invest In Investors are getting very rich in AI stocks right now. Wall Street legend is giving away the name and ticker of the little-known AI stock Wall Street is currently buying hand-over-fist.

Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"

About Senti Biosciences Stock (NASDAQ:SNTI)

Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

SNTI Stock Price History

30 days | 90 days | 365 days | Advanced Chart

SNTI Stock News Headlines

March 23, 2024 | finanznachrichten.de

Senti Biosciences, Inc.: Senti Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Reviews Recent Highlights

March 21, 2024 | globenewswire.com

Senti Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Reviews Recent Highlights

April 18, 2024 | Market Moving Trends (Ad)

Top 5 AI Stocks to Buy for 2024

February 4, 2024 | benzinga.com

Senti Biosciences Stock (NASDAQ:SNTI), Guidance and Forecast

January 8, 2024 | finanznachrichten.de

Senti Biosciences, Inc.: Senti Bio Announces Strategic Steps to Prioritize Investment in Lead Clinical Program

January 5, 2024 | marketwatch.com

Senti Biosciences to Cut Workforce by 37% to Focus on Potential Cancer Treatment

January 5, 2024 | finance.yahoo.com

Senti Bio Announces Strategic Steps to Prioritize Investment in Lead Clinical Program

December 22, 2023 | finance.yahoo.com

Why Is Blood Cancer Focused Senti Biosciences Stock Trading Higher Today?

April 18, 2024 | Market Moving Trends (Ad)

Top 5 AI Stocks to Buy for 2024

December 22, 2023 | markets.businessinsider.com

Senti Bio : FDA Clears IND Application For SENTI-202 For Treatment Of R/R Hematologic Malignancies

December 22, 2023 | finance.yahoo.com

Senti Bio Announces FDA Clearance of IND Application for SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia

November 24, 2023 | finanznachrichten.de

Senti Biosciences, Inc.: Senti Bio Announces Third Quarter 2023 Results and Pipeline Updates

November 13, 2023 | finance.yahoo.com

Senti Bio Announces Third Quarter 2023 Results and Pipeline Updates

November 11, 2023 | morningstar.com

Senti Biosciences Inc SNTI

November 7, 2023 | msn.com

Why Is Cell & Gene Therapy-Focused Senti Biosciences Stock Trading Higher Today?

November 7, 2023 | msn.com

Why Is Ventyx Biosciences (VTYX) Stock Down 76% Today?

November 7, 2023 | msn.com

Why Is Senti Biosciences (SNTI) Stock Up 140% Today?

November 6, 2023 | finance.yahoo.com

Senti Bio Announces New Strategic Collaboration with Celest Therapeutics for Clinical Development of SENTI-301A in China

October 31, 2023 | finance.yahoo.com

Senti Bio Announces Multiple Data Presentations at the Society for Immunotherapy of Cancer Annual Meeting

October 9, 2023 | bizjournals.com

Gene and cell therapy startup GeneFab takes over Senti Biosciences' Alameda manufacturing facility

September 27, 2023 | investing.com

Shanti Overseas India Ltd (SNTI)

September 27, 2023 | finance.yahoo.com

Senti Bio Announces Multiple Data Presentations at the Society for Immunotherapy of Cancer 2023 Meeting

September 26, 2023 | finance.yahoo.com

Senti Bio to Participate in Upcoming Conferences

August 15, 2023 | msn.com

Chardan Capital Reiterates Senti Biosciences (SNTI) Buy Recommendation

August 11, 2023 | finanznachrichten.de

Senti Biosciences, Inc.: Senti Bio Announces Second Quarter 2023 Results and Pipeline Updates

August 11, 2023 | finance.yahoo.com

Senti Bio Announces Second Quarter 2023 Results and Pipeline Updates

August 11, 2023 | finance.yahoo.com

Senti Biosciences, Inc. (SNTI) Reports Q2 Loss, Misses Revenue Estimates

See More Headlines

Receive SNTI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Senti Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/21/2024
Today: 4/17/2024
Next Earnings (Estimated): 5/14/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:SNTI
CUSIP: N/A
CIK: 1854270
Web: www.sentibio.com
Phone: 650-239-2030
Fax: N/A
Employees: 48
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $6.00
High Stock Price Target: $6.00
Low Stock Price Target: $6.00
Potential Upside/Downside: +1,835.5%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.60)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-71,060,000.00
Net Margins: -2,692.82%
Pretax Margin: -3,256.77%
Return on Equity: -74.59%
Return on Assets: -48.22%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 5.62
Quick Ratio: 5.62

Sales & Book Value

Annual Sales: $2.56 million
Price / Sales: 5.54
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.50 per share
Price / Book: 0.21

Miscellaneous

Outstanding Shares: 45,760,000
Free Float: 40,036,000
Market Cap: $14.19 million
Optionable: Not Optionable
Beta: 2.96

Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

Dr. Timothy K. Lu M.D. (Age 43)
Ph.D., Co-founder, CEO, President & Director
Comp: $811.26k
Dr. James J. Collins Ph.D. (Age 57)
Scientific Co-Founder, Chairperson of Scientific Advisory Board & Independent Director
Comp: $41.49k
Dr. Deborah A. Knobelman Ph.D. (Age 50)
CFO, Head of Corporate Development & Treasurer
Comp: $600.22k
Ms. Susan D. Berland (Age 69)
Senior Financial Executive & Independent Director
Comp: $54.23k
Dr. Kanya Rajangam M.D. (Age 51)
Ph.D., Head of Research & Development and Chief Medical Officer
Comp: $679.71k
Dr. Wilson Wong Ph.D.
Scientific Co-Founder & Member of Scientific Advisory Board
Mr. Mike Rhee
Senior VP of Legal Affairs & Corporate Secretary
Susan Kahlert
Controller

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

SNTI Stock Analysis - Frequently Asked Questions

Should I buy or sell Senti Biosciences stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Senti Biosciences in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SNTI shares.
View SNTI analyst ratings or view top-rated stocks.
What is Senti Biosciences' stock price target for 2024?: 1 equities research analysts have issued twelve-month target prices for Senti Biosciences' shares. Their SNTI share price targets range from $6.00 to $6.00. On average, they expect the company's stock price to reach $6.00 in the next twelve months. This suggests a possible upside of 1,835.5% from the stock's current price.
View analysts price targets for SNTI or view top-rated stocks among Wall Street analysts.
How have SNTI shares performed in 2024?: Senti Biosciences' stock was trading at $0.66 on January 1st, 2024. Since then, SNTI shares have decreased by 53.0% and is now trading at $0.31.
View the best growth stocks for 2024 here.
When is Senti Biosciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our SNTI earnings forecast.

How were Senti Biosciences' earnings last quarter?: Senti Biosciences, Inc. (NASDAQ:SNTI) issued its earnings results on Thursday, March, 21st. The company reported ($0.42) earnings per share (EPS) for the quarter. Senti Biosciences had a negative trailing twelve-month return on equity of 74.59% and a negative net margin of 2,692.82%.
What ETF holds Senti Biosciences' stock?: ARK Genomic Revolution ETF holds 1,560,153 shares of SNTI stock, representing 0.04% of its portfolio.
How do I buy shares of Senti Biosciences?: Shares of SNTI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SNTI) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Senti Biosciences (SNTI) Stock Price, News & Analysis

Senti Biosciences MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

Company Ownership

Earnings and Valuation

About Senti Biosciences Stock (NASDAQ:SNTI)

SNTI Stock Price History

SNTI Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

SNTI Stock Analysis - Frequently Asked Questions

Overall MarketRank^™